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Abstract
Context: Hepatocellular carcinoma (HCC) is a common disorder throughout the world that can develop due to various factors,
including genetics. Tumor necrosis factor-α (TNF-α) is the most frequently studied cytokine related to the risk of developing HCC,
and an association between the 308 position of the TNF-αpromoter (TNF-α-308) and HCC risk has been confirmed in various reports.
Evidence Acquisition: The PubMed, Scopus, and Google Scholar databases were searched through July 12, 2015, for studies on asso-
ciations between TNF-α-308 and the risk of HCC. To determine this association, odds ratios (ORs) and 95% confidence intervals (95%
CIs) were calculated.
Results: A total of 23 case-control studies were investigated, involving 3,389 cases and 4,235 controls. The overall conclusion was
that the A allele was more frequent in case groups compared to control groups (13.4% vs. 8.4%). Thus, the A allele was significantly
associated with increased HCC risk (OR = 1.77; 95% CI = [1.26-2.50]; P value < 0.002). In addition to the allelic model, the dominant
model (AA + AG vs. GG) was significantly associated with HCC risk (OR = 1.80; CI = [1.29-2.51]; P value < 0.001). In the sensitivity analysis
for co-dominant (AA vs. GG) and recessive models (AA vs. AG + GG), no trustworthy associations with the risk of HCC development
were observed.
Conclusions: This meta-analysis indicated that the TNF-α-308 G/A polymorphism is significantly associated with increased suscep-
tibility to HCC. However, to confirm this finding, more studies are needed on TNF-α-308 G/A polymorphisms associated with HCC.
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1. Context
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in men and the seventh in women (1), account-
ing for 70% - 85% of primary liver cancers (2). Hepatitis B
virus (HBV) and hepatitis C virus (HCV) infections are the
main causes of HCC; however, only a fraction of patients
with these infections will develop HCC during their life-
times. The prevalence of HCC is correlated with the inci-
dence of HBV and HCV in regions with a high risk of these
infections, such as Asia and Africa, where HBV and HCV are
the primary cause of HCC.
Tumor necrosis factor-α (TNF-α), which is associated
with HCC susceptibility, is a multi-functional cytokine that
helps to regulate different pathways involved in inflam-
mation, immunity, apoptosis, anti-apoptosis, and tumori-
genesis (3). TNF-α was first believed to be an anti-tumor
cytokine, but emerging evidence does not confirm this
role. New research has identified TNF-α in a majority of
cancers associated with inflammation, acting as a tumor-
promoting factor. Indeed, it plays two different roles as-
sociated with cancer: it can be an endogenous tumor-
promoter, or it can act as a cancer-killer (4) along with acti-
vated macrophages, which are the major source of TNF-α,
monocytes, lymphoid cells, and mast cells. TNF-α can also
be produced by various tumor cells, including breast can-
cer, B-lymphoma, and colon carcinoma. Considerable re-
search has confirmed the role of TNF-α in the promotion
and progression of human cancers. It can cause activation
of activator protein 1 (AP-1) and nuclear factor-kappa B (NF-
κB) transcription factors through different pathways (5).
In some studies, TNF-α expression was elevated in HCC pa-
tients (6, 7); however, in other studies, a lower level of TNF-
α was reported in HCC patients compared to healthy con-
trols (8, 9). The critical role of TNF-α in HBV reactivation
was also recently discussed by author (10).
Many studies have been performed on the association
between the frequency of susceptible TNF-α promoter al-
leles and HCC development. The most-studied polymor-
phism of TNF-α promoter positions in HCC development
risk are -308 G/A, -238 G/A, -857 C/T, and -863 C/A.
Wilson et al. (11) identified a biallelic polymorphism
in the TNF-α promoter at position -308 (TNF-α-308), which
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was introduced as G to A transition polymorphism. The A
allele is significantly less common than the G allele glob-
ally. It has been suggested that TNF-α-308 influences gene
expression (12). The A allele in TNF-α-308 results in a higher
constitutive and inducible level of TNF expression com-
pared to the G allele (13). All of these studies indicate the
importance of TNF-α-308 polymorphisms in the risk of
HCC development.
2. Evidence Acquisition
2.1. Publication Search
A systematic literature search for all published articles
related to HCC and TNF-α-308 polymorphisms was con-
ducted using the databases of PubMed, Scopus, and Google
Scholar. The last search update was on July 12, 2015, using
the keywords “tumor necrosis factor-α” or “tumor necrosis
factor-alpha” or “TNF-α”, “polymorphism” or “genotype” or
“SNP”, and “hepatocellular carcinoma” or “HCC” or “liver
cancer”. The references for the selected articles were also
checked for further related studies.
2.2. Selection Criteria
The inclusion criteria were:
1) The study design must be case-control.
2) The outcome should be HCC.
3) The study must include at least two groups, includ-
ing a case group and a control group.
4) The frequency of alleles and genotypes for both
groups, case and control, must be given or calculated.
5) The full article must be published in the English lan-
guage.
Review articles, systematic reviews, and meta-analyses
were excluded, but their references were checked for pos-
sible eligible studies based on the above criteria.
2.3. Data Extraction
The essential data were extracted from each article by
both of the authors independently. All of the extracted
data, including year of publication, country, study period,
genotyping method, number of cases and controls, and
frequency of genotypes and alleles, were categorized, then
entered into our database. Any disagreement was dis-
cussed until a consensus was reached.
2.4. Statistical Analysis
Statistical analyses were carried out using Comprehen-
sive Meta-Analysis (CMA) software, version 2. Odds ra-
tios (ORs) and 95% confidence intervals (CIs) were used
to measure the association between TNF-α-308 polymor-
phisms and the risk of HCC development. A P < 0.05 was
considered statistically significant. Heterogeneity among
the studies was examined with the Cochran Q test and I2
statistics. When significant heterogeneity was observed
(pheterogeneity < 0.1 and I2 > 50%), the random effect
model was used. However, in homogeneous conditions
(pheterogeneity > 0.1 and I2 < 50%), the fixed-effect model
was employed. Publication bias was investigated visually
with funnel plots. For calculation of overall effect size in
the absence of one study, a sensitivity analysis was con-
ducted. In this meta-analysis, both the allelic and the geno-
type genetics models, including per-allele (A vs. G), co-
dominant (AA vs. GG), dominant (AA + AG vs. GG), and re-
cessive models (AA vs. AG + GG), were analyzed in order to
evaluate the associations between the TNF-α-308 G/A allele
and HCC development risk.
3. Results
3.1. Publication Search
A total of 287 articles were identified in the database
search. Only articles in the English language were chosen
for primary screening. After omitting 53 duplicate stud-
ies, 234 articles were considered for skimming of titles and
abstracts, and 52 articles were subsequently selected for
careful scanning of the context. More than half of these
(29 studies) were excluded because they contained insuffi-
cient or non-relevant data for this analysis. Finally, 23 eligi-
ble studies were entered into our meta-analysis (Figure 1).
In three of these studies, the GA and AA genotypes were re-
ported in overall form instead of separately, so they could
be included only in the dominant-model analysis. Table
1 shows the summary of exported data from all of the in-
cluded studies.
3.2. Association Between the TNF-α-308 G/A Polymorphism
Mmodels and HCC Rrisk
Figure 2 indicates the association of the allelic model
(A vs. G) and the risk of HCC. Overall, the A allele was iden-
tified more frequently in HCC patients than in controls
(13.4% vs. 8.4%, respectively). Talaat et al. (14) were the only
authors to report a statistically significant difference from
the overall result. In analyzing the allelic model, because
of high heterogeneity (Pheterogeneity < 0.001, I2 = 85%), a
random effect model was used. Figure 2 shows that mutant
allele A in TNF-α-308 was related to increased HCC risk (P =
0.001, OR [95% CI] = 1.77 [1.26-2.50]). For the co-dominant
model (AA vs. GG), considering the significant heterogene-
ity among the studies (Pheterogeneity = 0.003, I2 = 55%), a
random-effect model was employed. The analysis of the co-
dominant model (P < 0.020, OR [95% CI] =2.14 [1.13-4.06]),
shown in Figure 3, identified a possible association with
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HCC risk, but this result may be influenced by removing
one study. Therefore, we deduced that this result was not
reliable.
Due its significant heterogeneity (Pheterogeneity =
0.006, I2 = 52%), a random model was used for the recessive
model (Figure 4), showing a statistically significant associ-
ation with the HCC risk (P < 0.047, OR [95% CI] =1.83 [1.01-
3.33]). However, similar to the co-dominant model, its re-
sults were not trustworthy. After analyzing the results of
selected articles for the dominant model, it was noted that
there was a significant association between this model in
TNF-α-308 and the risk of HCC development (P < 0.001, OR
[95% CI] =1.80 [1.29-2.51]). This association is clearly shown
in Figure 5. Considering the high heterogeneity (Phetero-
geneity < 0.001, I2 = 81%) among the selected studies, the
random model was used instead of the fixed model in the
dominant model. Table 2 also summarizes the most impor-
tant results for all four of the analyzed models.
3.3. Sensitivity Analysis
After checking the effect of omitting any given study
with a sensitivity analysis, the results of the allelic and
dominant models were concluded to be completely reli-
able, while the other two models were considered unreli-
able because of alterations of the overall results in the sen-
sitivity analysis. Figure 6 shows the sensitivity analysis re-
sults for the analyzed models.
3.4. Publication Bias
To evaluate for any evidence of publication bias among
the included studies, funnel plots for all four of the models
were performed (Figure 7). The shape of these plots sug-
gested no evidence of publication bias among the studies.
4. Conclusions
There are several risk factors for HCC development, in-
cluding cirrhosis, HBV, HCV, toxins, drinking-water con-
tamination, and alcohol (37). HCC most often develops as
an outcome of HBV or HCV infections, which can be af-
fected by various factors (38, 39). Various cytokines and
cells are deeply involved in several types of diseases, such
as HCC and viral hepatitis. Having a plan of their activity
and functions may lead to the emergence of new therapeu-
tic options and also better management of HBV infection
(40, 41). For example, recently, Tavakolpour (41) used the
function of cytokines and cells to introduce a new thera-
peutic approach for chronic HBV. Finding the association
between TNF-α polymorphisms may also lead to the emer-
gence of some options to better management of HCC. TNF-
α is also involved in HCC development (42, 43). TNF-αpoly-
morphisms can regulate the expression of this cytokine,
and different meta-analyses have shown an association be-
tween TNF-α-308 G/A and the risk of HCC (44-47). However,
the results for TNF-238 G/A in this context have been contro-
versial (44-46, 48). Furthermore, there is limited evidence
of an association between HCC and TNF-863 C/A, and no as-
sociation between TNF-857 C/T or TNF-1031 T/C and the risk
of HCC (19). Table 3 summarizes the results of recent meta-
analyses that sought to identify links between HCC risk and
different positions of TNF-α promoter.
The present meta-analysis investigated associations be-
tween TNF-α-308 G/A and the risk of HCC in an allelic model
and all genotype models. The results for the allelic model,
reflecting 20 studies, indicated a significant association
with HCC risk. This is similar to the results reported by
Wang et al. (47), Hu et al. (46), and Cheng et al. (48). Due to
high heterogeneity, the random model was employed for
this analysis.
In addition to the A vs. G model, the AA vs. GG model
was associated with HCC. However, Hu et al. (46) and Cheng
et al. (48) did not report a relationship between this model
and HCC risk. Thus, the present meta-analysis introduced
an association between a co-dominant genotype model
with HCC for the first time. However, a sensitivity analysis
showed that these results should be considered unreliable.
Thus, further studies are necessary to determine whether
there is any significant association in this regard. In a re-
cessive model, the P value was very close to 0.05, indicat-
ing statistical significance, but this was not trustworthy, as
the sensitivity analysis found no association on the reces-
sive model between HCC risk and TNF-α-308. Similar to our
analysis, all of the published meta-analyses found no rela-
tionship on the recessive model.
For the dominant model, similar to all of the previ-
ously published meta-analyses, a significant association
with HCC was found in the present study, confirming the
previous results.
In all of the models, significant heterogeneity was ob-
served. Thus, a random model was used for the analyses.
In the allelic and dominant models, which were consid-
ered significantly associated with HCC in previous anal-
yses, an association with HCC was also obtained in this
study. However, this relationship may possibly exist in the
co-dominant and recessive models. Differentiation of this
result with previous studies was associated with the co-
dominant model, which was not calculated in most of the
other meta-analyses. Among all of the published results,
Talaat’s study was considerably different from the others,
reporting the G allele as a risk factor for HCC. This research
was carried out in Egyptian patients with chronic HCV in-
fections. Two other studies investigated Egyptian popula-
tions, but all of them introduced the A allele as a risk factor
for HCC. Our results also confirmed the A allele risk factor.
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287 Potentially Relevant Article in
English language
53 Articles Excluded Due to Duplication
182 Studies Were Excluded With Abstract and Title
Because of Non-Relevant Data
234 Studies Were Considered for More
Evalution
52 Studies Were Read Carefully
23 Studies Were Considered in Our
Meta-Analysis
29 Studies Were not Suitable for our Meta-Analysis
(Useless Data, Non-Relevant, Non-Extractable Data,
Insufficient Data)
Figure 1. Flow Chart for Identifying Potential Studies for the Meta-Analysis
In other HCV cases that developed HCC, the results were
not as different as they were in this study.
A sensitivity analysis, which removes one study and re-
peats the analysis, may reveal that the overall results de-
pend on a certain study or not. After the sensitivity analy-
sis in the present study, the reliability of the final results,
which showed associations between the allelic and the
dominant models with HCC, was confirmed. Despite an
association of the co-dominant and recessive models with
HCC, based on the sensitivity analysis results, this associa-
tion was not trustworthy.
The present meta-analysis may suffer from certain lim-
itations. First, only English-language studies were in-
cluded, although there are studies published in other lan-
guages, especially Chinese. Another limitation is the high
heterogeneity of the data, which can cause deviations from
factual results. Environmental factors and primary dis-
eases that cause HCC should also be considered, but this
was impractical with the low number of included stud-
ies. In this analysis, it was assumed that all of the enrolled
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Table 1. Main Characteristics of the Studies Included in the Meta-Analysis
Study, y Ref Country Study Period GenotypingMethod Case Control
N GG GA AA N GG GA AA
Wang, 2003 (15) Japan 2000 - 2001 Direct sequencing 125 109 15 1 55 48 6 1
Ben-Ari, 2003 (16) Israel NM PCR-SSP 10 9 1a 48 42 6a
Heneghan, 2003 (17) China NM PCR 98 88 10 0 172 158 13 1
Ho, 2004 (18) China 2000 - 2003 PCR 74 37 34 3 289 225 62 2
Niro, 2005 (19) Italy 2000 - 2003 Direct sequencing 30 24 6a 96 75 21a
Migita, 2005 (20) Japan 2000 - 2004 PCR-SSP 48 47 1 0 188 183 5 0
Chen, 2005 (21) China 1997 - 2001 PCR-RFLP 572 468 95 9 381 311 67 3
Kummee, 2007 (22) Thailand NM PCR-RFLP 50 42 6 2 150 123 15 12
Jeng, 2007 (23) China 2001 - 2001 PCR 108 80 28 0 108 100 8 0
Sakamoto, 2008 (24) Japan 2001 - 2004 PCR-RFLP 209 205 4 0 275 270 5 0
Jeng, 2009 (25) China 2003 - 2004 PCR 200 149 50 1 200 188 12 0
Ognjanovic, 2009 (26) US 1984 - 2001 TaqMan 118 90 28a 225 176 49a
Akkiz, 2009 (27) Turkey 2005 - 2007 PCR-RFLP 110 72 35 3 110 99 11 0
Wang, 2010 (28) China NM PCR 230 197 30 3 158 143 15 0
Shi, 2011 (29) China 2007 - 2009 PCR-RFLP 88 30 43 15 88 45 35 8
Shi, 2012 (30) China 2000 - 2010 PCR-RFLP 73 51 20 2 116 84 30 2
Radwan, 2012 (31) Egypt NM PCR-RFLP 128 82 42 4 160 136 24 0
Talaat, 2012 (14) Egypt NM TaqMan 45 42 2 1 45 25 13 7
Teixeira, 2013 (32) Brazil 2001-2009 PCR 111 81 30 0 202 173 26 3
Saxena, 2013 (33) India NM PCR-RFLP 59 52 7 0 139 128 11 0
Feng, 2014 (34) China 2010 - 2013 PCR 753 611 98 44 760 733 25 2
Rizk, 2014 (35) Egypt NM PCR 50 25 15 10 70 56 8 6
Sghaier, 2015 (36) Tunis 2012 - 2013 PCR-RFLP 100 25 47 28 200 80 72 48
a AA + GA value.
Table 2. Summarized Results of Pooled ORs in the Meta-Analysis
Model No. of Studies EmployedModel OR [95% CI] P Value Pheterogeneity I
2 , %
A vs. G 20 Random 1.77 [1.26-2.50] < 0.002 < 0.001 85
AA vs. GG 20 Random 2.14 [1.13-4.06] < 0.020 0.003 55
AA vs. AG + GG 20 Random 1.83 [1.01-3.33] < 0.047 0.006 52
AA + AG vs. GG 23 Random 1.80 [1.29-2.51] < 0.001 < 0.001 81
Table 3. Summary of Previous Meta-Analysis Results for Different TNF-α Promoter Positions
Study, y Ref Region -308 G/A -238 G/A -857 C/T -863 C/A -1031 T/C
Yang, 2010 (44) Global Associated Not associated
Wei, 2011 (45) Asia Associated Associated Not associated Associated Not associated
Cheng, 2013 (48) Global Associated
Hu, 2014 (46) Asia Associated Not associated
Wang, 2014 (47) Han Chinese Associated
studies contained accurate data; however, this may not be
true. On the other hand, there were also some advantages
in this analysis that previous studies lacked. For example,
this meta-analysis included 23 studies, which is the highest
number among similar meta-analyses. The last update of
the literature search was on July 12, 2015, which is consid-
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Figure 2. ORs and CIs of HCC risk Associated With TNF-α-308 G/A for the A Allele in Comparison to the G Allele (Allelic Model)
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Figure 3. ORs and CIs of HCC risk Associated With TNF-α-308 G/A for the AA Genotype Compared to the GG Gonotype (co-Dominant Effect)
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Figure 4. ORs and CIs of HCC risk Associated With TNF-A-308 G/A for the AA Genotype Compared to the AG + GG Genotype (Recessive Effect)
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Figure 5. ORs and CIs of HCC risk Associated With TNF-α-308 G/A for the AA + AG Genotype Compared to the GG Genotype (Dominant Effect)
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Figure 6. Results of Sensitivity Analysis for the Four Models
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Figure 7. Funnel Plot Analysis to Examine Publication Bias for all Analyzed Models
erably more recent than the last meta-analysis. To obtain
more valid and reliable results, future studies are needed.
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